Shares of Mallinckrodt PLC (NYSE:MNK) have received an average rating of “Hold” from the twenty-two brokerages that are currently covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a sell recommendation, twelve have issued a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $39.52.
A number of equities research analysts have issued reports on MNK shares. Zacks Investment Research downgraded Mallinckrodt from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Piper Jaffray Companies set a $67.00 price objective on Mallinckrodt and gave the company a “buy” rating in a research report on Saturday, October 21st. Cantor Fitzgerald reaffirmed a “buy” rating and set a $52.00 price objective on shares of Mallinckrodt in a research report on Thursday, November 2nd. Deutsche Bank cut Mallinckrodt from a “buy” rating to a “hold” rating and lowered their price objective for the company from $44.00 to $28.00 in a research report on Tuesday, November 7th. Finally, Citigroup cut Mallinckrodt from a “buy” rating to a “hold” rating and lowered their price objective for the company from $44.00 to $28.00 in a research report on Tuesday, November 7th.
In other Mallinckrodt news, Director Dr Kneeland Youngblood purchased 4,560 shares of the stock in a transaction that occurred on Tuesday, November 28th. The shares were bought at an average cost of $21.94 per share, with a total value of $100,046.40. Following the acquisition, the director now owns 19,789 shares in the company, valued at $434,170.66. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.53% of the stock is currently owned by insiders.
Shares of Mallinckrodt (NYSE MNK) opened at $15.96 on Wednesday. The stock has a market capitalization of $1,567.58, a PE ratio of 2.23, a price-to-earnings-growth ratio of 0.31 and a beta of 1.04. Mallinckrodt has a 52 week low of $15.27 and a 52 week high of $55.32. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.05 and a current ratio of 1.38.
TRADEMARK VIOLATION NOTICE: “Mallinckrodt PLC (MNK) Given Average Rating of “Hold” by Brokerages” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/14/mallinckrodt-plc-mnk-given-average-rating-of-hold-by-brokerages.html.
Mallinckrodt Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.